A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe: A Follow-up Physician Survey
1 other identifier
observational
454
1 country
1
Brief Summary
With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire. The questionnaire will gather information related to physician characteristics and experience with Aflibercept, as well as assess physicians' knowledge and understanding of storage and preparation, proper injection technique, and the risks associated with Aflibercept injection into the eye (intravitreal injection). Analysis will be done using descriptive statistics.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 22, 2019
CompletedFirst Posted
Study publicly available on registry
August 26, 2019
CompletedStudy Start
First participant enrolled
October 8, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 15, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
April 23, 2020
CompletedApril 8, 2021
April 1, 2021
6 months
August 22, 2019
April 6, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of physicians responding correctly to each individual knowledge question
Up to 1 year
Study Arms (1)
Physicians with recent aflibercept experience
Ophthalmologists who have prescribed and/or administered aflibercept in the past 6 months
Interventions
This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
Eligibility Criteria
The source of information for the study will be self-reported data collected from physicians using standard questionnaires with closed-ended response choices. Countries included are France, Germany, Italy, Spain, and the United Kingdom.
You may qualify if:
- Has signed informed consent
- Is a licensed and practicing ophthalmologist
- Has prescribed and/or administered aflibercept to at least one patient in the past 6 months
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayerlead
Study Sites (1)
Many locations
Multiple Locations, Germany
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 22, 2019
First Posted
August 26, 2019
Study Start
October 8, 2019
Primary Completion
April 15, 2020
Study Completion
April 23, 2020
Last Updated
April 8, 2021
Record last verified: 2021-04